➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKesson

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Patent: 8,217,020

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,217,020
Title:Methods and compositions for reducing viral genome amounts in a target cell
Abstract: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
Inventor(s): Sarnow; Peter (Palo Alto, CA), Jopling; Catherine L. (Liverpool, GB), Lancaster; Alissa M. (Portland, OR)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Application Number:12/950,672
Patent Claims:see list of patent claims

Details for Patent 8,217,020

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2024-05-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2024-05-04
Kadmon Pharmaceuticals Llc INFERGEN interferon alfacon-1 Injection 103663 1997-10-06 ⤷  Try it Free 2024-05-04
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 2004-06-04 ⤷  Try it Free 2024-05-04
Schering Corporation A Subsidiary Of Merck & Co., Inc. PEGINTRON/ REBETOL COMBO PACK peginterferon alfa-2b and ribavirin 125196 2008-06-13 ⤷  Try it Free 2024-05-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
AstraZeneca
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.